Traws Pharma Announces Up to $60 Million Financing

Traws Pharma has announced a private placement financing round expected to raise up to $60 million. The financing, led by Sirenia Capital Management LP, will support the advancement of Traws Pharma's influenza program. Specifically, the funds will facilitate a human challenge trial for its drug candidate, tivoxavir marboxil. This crucial trial aims to evaluate the efficacy of the drug in a controlled setting. The successful completion of this financing is a significant step for Traws Pharma's drug development pipeline.